Ewelina Kulikowski - Resverlogix Corp Chief Officer

All Insiders . USA . 
Stock . Resverlogix Corp . Stakeholders . Insider . Ewelina Kulikowski
RVXCF Stock  USD 0.04  0.00  0.00%   

Insider

Ewelina Kulikowski is Chief Officer of Resverlogix Corp
Phone403 254 9252
Webhttps://www.resverlogix.com

Resverlogix Corp Management Efficiency

The company has return on total asset (ROA) of (0.9632) % which means that it has lost $0.9632 on every $100 spent on assets. This is way below average. Resverlogix Corp's management efficiency ratios could be used to measure how well Resverlogix Corp manages its routine affairs as well as how well it operates its assets and liabilities.
Resverlogix Corp has accumulated 53.27 M in total debt. Resverlogix Corp has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Resverlogix Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Resverlogix Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Resverlogix Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Resverlogix to invest in growth at high rates of return. When we think about Resverlogix Corp's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Thomas LynchBiohaven Pharmaceutical Holding
N/A
Greg LeszczynskiCovalon Technologies
N/A
Steven BellonFoghorn Therapeutics
59
Hans MDImmunitybio
74
Erin LavelleEliem Therapeutics
47
Elyse StockBiohaven Pharmaceutical Holding
63
Simon SmithCovalon Technologies
N/A
Jean EpinatCellectis SA
N/A
Vladimir MDBiohaven Pharmaceutical Holding
53
Lina GuguchevaNewAmsterdam Pharma
37
Susan MSEliem Therapeutics
N/A
Mark LappeInhibrx
57
MBA MDEliem Therapeutics
63
Jo PalmerPhillipsEliem Therapeutics
N/A
David SachsImmunitybio
46
MPH MDFoghorn Therapeutics
51
Mark GowlandFennec Pharmaceuticals
N/A
Warren VollesBiohaven Pharmaceutical Holding
N/A
Joshua MBACentessa Pharmaceuticals PLC
50
FESC MDNewAmsterdam Pharma
68
FACC FaccNewAmsterdam Pharma
65
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. RESVERLOGIX CORP operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 22 people. Resverlogix Corp [RVXCF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Asset-0.96

Resverlogix Corp Leadership Team

Elected by the shareholders, the Resverlogix Corp's board of directors comprises two types of representatives: Resverlogix Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Resverlogix. The board's role is to monitor Resverlogix Corp's management team and ensure that shareholders' interests are well served. Resverlogix Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Resverlogix Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Donald McCaffrey, Co-Founder, CEO and President Secretary and Director
Ewelina Kulikowski, Chief Officer
Sarah Zapotichny, Director Communications
Michael MD, VP Devel

Resverlogix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Resverlogix Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.96
Current Valuation36.3 M
Shares Outstanding265.27 M
Shares Owned By Insiders44.51 %
Price To Earning11.36 X
EBITDA(22.93 M)
Net Income(24.77 M)
Cash And Equivalents42 K
Total Debt53.27 M
Current Ratio0.14 X

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in Resverlogix Pink Sheet

Resverlogix Corp financial ratios help investors to determine whether Resverlogix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Resverlogix with respect to the benefits of owning Resverlogix Corp security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY